Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Next generation gene writing platform to cure genetic and oncological diseases

Project description

Gene writing platform for genetic disease treatment

Gene therapy can treat over 10 000 genetic diseases and conditions such as cancer by repairing harmful genetic defects or engineering immune cells. However, many genetic disorders remain untreatable due to the limitations of current editing technologies, which often lack efficiency, precision, and safety. The EIC-funded FiCAT project seeks to overcome these barriers by developing an advanced gene-writing technology that combines RNA-guided nucleases with programmable transposases. This platform enables the safe and precise insertion of large DNA segments into the genome, achieving high integration efficiency and validated performance across multiple models. The FiCAT platform has the potential to transform treatments for genetic and neoplastic diseases, offering new hope for patients with unmet medical needs.

Objective

Gene therapy offers a promising opportunity for treating the more than 10,000 human genetic diseases, as well as other disorders, such as cancer, by editing disease-causing genetic defects or engineering immune cells to target cancer cells. However, most genetic disorders remain untreatable, as gene therapy still holds an untapped potential due to significant limitations of current editing technologies, that are not efficient, precise and safe enough and thus, present limitations in scope and applicability.
Integra Therapeutics, a spin-off of the Pompeu Fabra University (UPF) has developed an advanced genome writing platform that overcomes the limitations of current gene editing technologies. Our proprietary gene writing technology platform- FiCAT combines the precision of RNA-guided nucleases with the effectiveness of programmable transposases to insert large pieces of DNA in a safe, precise and stable way. FiCAT has the capacity to integrate virtually any gene into the genome with unprecedented efficiency, precision and safety. FICAT has already been validated in several ex vivo and in vivo models. With FiCAT, we will unlock the potential of gene writing to cure genetic diseases and bring life-changing therapies to patients suffering from high unmet need genetic and neoplastic diseases.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

INTEGRA THERAPEUTICS S.L.
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 496 375,00
Address
CARRER DOCTOR AIGUADER 88
08003 Barcelona
Spain

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0